Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.